BIO-RAD LABORATORIES, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $28.1m
$122.2m +334.66%
$365.6m +199.07%
$1.8b +381.02%
$3.8b +116.43%
$4.2b +11.55%
($3.6b) -185.44%
($637.3m) +82.43%
($1.8b) -189.37%
$759.9m +141.20%
Depreciation, Depletion and Amortization $142.9m $148.7m $138.1m $134.2m $138.1m $133.8m $137.3m $145.9m $151.6m $165.4m $168.7m
Amortization of Intangible Assets $35.2m $30.8m $28.3m $23.5m $27.5m $28.4m $24.9m $23.8m $21.2m $23.8m
Depreciation $141.4m $168.7m
Depreciation, Amortization and Accretion, Net $40.3m $37.1m $39.3m $39.9m $46.5m $41.2m $40.0m $168.7m
Deferred Income Tax Expense (Benefit) ($51.2m) ($84.8m) $120.9m $450.2m $979.0m $1.1b ($1.2b) ($322.6m) ($626.8m) $170.5m
Share-based Payment Arrangement, Noncash Expense $19.7m $23.4m $27.8m $35.6m $41.6m $51.2m $60.9m $61.3m $62.3m $58.0m $60.3m
Payment, Tax Withholding, Share-based Payment Arrangement $8.9m $8.1m $12.9m $22.5m $14.0m $14.9m $3.4m $3.0m
Share-based Payment Arrangement, Expense $19.7m $23.4m $27.8m $35.6m $41.6m $51.2m $60.9m $61.3m $62.3m $58.0m $60.3m
Equity Method Investment, Other than Temporary Impairment $800k $11.9m $0 $0 $6.0m
Goodwill, Impairment Loss $13.5m $11.5m $282.0m $0 $0 $0 $0 $0 $178.8m
Impairment of Intangible Assets (Excluding Goodwill) $172.8m
Impairment of Intangible Assets, Finite-lived $0 $0 $0 $0 $0 $0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $46.4m
Nonoperating Income (Expense) $0
Other Nonoperating Income (Expense) $14.8m $12.2m $36.6m $26.1m $24.5m $26.8m $44.6m $106.4m $90.3m $90.3m
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable ($12.5m) $64.1m ($59.7m) ($1.6m) $15.0m $20.4m $87.4m ($11.4m) ($16.2m) ($19.6m) $21.3m
Increase (Decrease) in Inventories $57.1m $47.7m $12.9m ($24.2m) $52.1m ($46.1m) $158.8m $46.3m ($8.5m) ($68.9m) $27.5m
Gain (Loss) on Disposition of Other Assets $5.1m $0 $11.7m $0 $1.4m $0 $0
Net Cash Provided by (Used in) Operating Activities $216.4m
$103.9m -52.00%
$285.5m +174.82%
$457.9m +60.39%
$575.3m +25.65%
$656.5m +14.11%
$194.4m -70.38%
$374.9m +92.83%
$455.2m +21.41%
$532.2m +16.92%
$492.6m -7.44%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $141.4m $111.3m $129.8m $98.5m $98.9m $120.8m $112.8m $156.7m $165.6m $157.6m ($139.5m)
Gain (Loss) on Disposition of Property Plant Equipment ($600k) ($8.1m) ($2.0m) ($1.2m) ($1.1m) ($120.8m) ($112.8m) ($156.7m) ($165.6m) ($157.6m)
Marketable Securities, Unrealized Gain (Loss) ($2.7b) $900.4m
Payments to Acquire Investments $278.1m $282.7m $371.0m $371.4m $248.5m $851.6m $2.1b $689.0m $1.3b $669.3m ($773.0m)
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale $143.0m $202.2m $225.3m $226.9m $278.3m $341.4m $357.8m $361.3m $199.3m $62.0m
Payments for (Proceeds from) Other Investing Activities ($3.4m) $0 $1.4m $0 $0
Net Cash Provided by (Used in) Investing Activities ($213.9m) ($175.6m) ($187.0m) ($208.9m) ($60.2m) ($784.4m) ($1.2b) $20.2m ($160.2m) ($189.7m) ($237.1m)
Cash flows from financing activities:
Repayments of Long-term Debt $303k $316k $3.0m $643k $426.9m $3.0m $510k $467k $400k $500k ($500k)
Debt and Equity Securities, Gain (Loss) $1.6m $1.5m $700k
Debt and Equity Securities, Unrealized Gain (Loss) $4.9b ($5.2b) ($1.3b) ($2.7b) $900.4m
Payments for Repurchase of Common Stock $2.9m $48.9m $28.0m $100.0m $50.0m $215.7m $428.7m $203.6m $295.5m
Proceeds from Issuance of Common Stock $11.3m $7.3m $14.1m $5.0m $7.3m ($1.9m) ($3.4m) $18.5m $19.2m $15.8m
Net Cash Provided by (Used in) Financing Activities $9.0m
$341k -96.22%
($48.7m) -14375.66%
($22.8m) +53.25%
($523.0m) -2198.27%
($55.4m) +89.40%
$973.6m +1856.44%
($425.6m) -143.72%
($218.8m) +48.60%
($283.2m) -29.43%
($120.8m) +57.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4.5m ($196.0m) ($36.6m) ($30.2m) $85.4m $42.4m $506.4m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $434.2m $662.7m $667.1m $471.1m $434.5m $404.4m $489.8m $532.2m $506.4m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $38.4m $52.1m $62.4m $45.1m $65.2m $134.7m $158.3m $129.6m $99.4m $61.6m
Additional Financial Items
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement ($1.2m) $0 ($900k) ($1.3m) $1.2m ($200k) ($1.3m) ($2.2m) ($1.3m)
Fair Value, Option, Changes in Fair Value, Gain (Loss) $100.6m $6.8m ($12.5m) ($12.4m)
Foreign Currency Transaction Gain (Loss), before Tax ($4.5m) ($9.1m) ($2.9m) ($2.2m) ($1.8m) ($2.8m) $205k $7.3m $3.9m $6.6m
Foreign Currency Transaction Gain (Loss), Realized ($19.9m) $9.9m ($20.7m) $43.5m
Gain (Loss) on Disposition of Assets $4.1m $0 $0
Gain (Loss) on Disposition of Business ($11.7m) $0 ($1.4m) ($2.5m) $0 $0
Goodwill $477.1m $506.1m $219.8m $264.1m $291.9m $347.3m $406.5m $413.6m $410.5m $579.8m $178.8m
Income Tax Expense (Benefit) $13.4m ($24.4m) $147.0m $502.4m $1.1b $1.2b ($1.1b) ($212.8m) ($498.3m) $235.6m
Provision for Loan, Lease, and Other Losses $7.5m $0 $0 $1.4m
Realized Investment Gains (Losses) $800k $100k $1.6m $1.5m $1.0m $8.0m $2.3m $700k $6.7m $1.0m
Revenue from Contract with Customer, Including Assessed Tax $2.3b $2.3b $2.5b $2.9b $2.8b $2.7b $2.6b $2.6b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.